MCID: ULC008
MIFTS: 24

Ulcerative Proctitis

Categories: Rare diseases, Gastrointestinal diseases

Aliases & Classifications for Ulcerative Proctitis

MalaCards integrated aliases for Ulcerative Proctitis:

Name: Ulcerative Proctitis 49
Chronic Ulcerative Proctitis 69

Classifications:



External Ids:

ICD10 32 K51.2
UMLS 69 C2937222

Summaries for Ulcerative Proctitis

NIH Rare Diseases : 49 Ulcerative proctitis is a type of ulcerative colitis that affects the rectum. The symptoms of this form of proctitis may include bleeding from the rectum, the need to go to the bathroom frequently, tenesmus, diarrhea or constipation, and rectal pain. People with ulcerative proctitis tend to have episodes when the symptoms worsen and periods without symptoms, although the course of the disease varies among affected individuals. Treatment involves applying 5-aminosalicylic acid (5-ASA) or steroid creams to the rectum. In some cases, an oral version of 5-ASA is used to prevent episodes. Last updated: 12/11/2012

MalaCards based summary : Ulcerative Proctitis, also known as chronic ulcerative proctitis, is related to proctitis and colitis. An important gene associated with Ulcerative Proctitis is CRP (C-Reactive Protein). The drugs Tacrolimus and Immunosuppressive Agents have been mentioned in the context of this disorder. Affiliated tissues include monocytes.

Related Diseases for Ulcerative Proctitis

Diseases related to Ulcerative Proctitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 20)
# Related Disease Score Top Affiliating Genes
1 proctitis 10.8
2 colitis 10.3
3 ulcerative colitis 10.3
4 mungan syndrome 10.0
5 mucositis 9.9
6 lymphogranuloma venereum 9.8
7 pericarditis 9.8
8 constipation 9.8
9 blood group--diego system 9.8
10 intestinal pseudo-obstruction 9.8
11 systemic lupus erythematosus 9.8
12 lupus erythematosus 9.8
13 pelvic organ prolapse 9.8
14 lymphomatoid papulosis 9.8
15 gallbladder disease 1 9.8
16 cytomegalovirus infection 9.8
17 crohn's disease 9.8
18 hemolytic anemia 9.8
19 neutropenia 9.8
20 inflammatory bowel disease 9.8

Graphical network of the top 20 diseases related to Ulcerative Proctitis:



Diseases related to Ulcerative Proctitis

Symptoms & Phenotypes for Ulcerative Proctitis

Drugs & Therapeutics for Ulcerative Proctitis

Drugs for Ulcerative Proctitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
2 Immunosuppressive Agents Phase 4
3 Calcineurin Inhibitors Phase 4
4
Budesonide Approved Phase 3,Phase 2 51333-22-3 5281004 63006
5 Mesalamine Phase 3,Phase 2 89-57-6
6 Analgesics Phase 3,Phase 2
7 glucocorticoids Phase 3,Phase 2
8 Respiratory System Agents Phase 3,Phase 2
9 Analgesics, Non-Narcotic Phase 3,Phase 2
10 Hormone Antagonists Phase 3,Phase 2
11 Hormones Phase 3,Phase 2
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
13 Peripheral Nervous System Agents Phase 3,Phase 2
14 Anti-Asthmatic Agents Phase 3,Phase 2
15 Anti-Inflammatory Agents Phase 3,Phase 2
16 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2
17 Autonomic Agents Phase 3,Phase 2
18 Antirheumatic Agents Phase 3,Phase 2
19 Bronchodilator Agents Phase 3,Phase 2
20 Cola Nutraceutical Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
2 The Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis Completed NCT01349673 Phase 3 Budesonide Foam
3 Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008423 Phase 3 Budesonide;Placebo
4 Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008410 Phase 3 Budesonide;Placebo
5 Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis Terminated NCT01016262 Phase 3 MAX-002;Placebo;Canasa®
6 Clinical Trial With Mesalamine 1g Suppositories Terminated NCT01172444 Phase 3 Mesalamine;Canasa;Placebo
7 Assessment of Photopill Capsule Treatment for Safety and Feasibility in Ulcerative Proctitis Completed NCT01837615 Phase 2
8 Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis Completed NCT01966783 Phase 2 Budesonide 2 mg suppository;Budesonide 4 mg suppository;Mesalazine 1 g suppository;Budesonide 2 mg suppository/Mesalazine 1 g suppository
9 Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis Recruiting NCT03259659

Search NIH Clinical Center for Ulcerative Proctitis

Genetic Tests for Ulcerative Proctitis

Anatomical Context for Ulcerative Proctitis

MalaCards organs/tissues related to Ulcerative Proctitis:

38
Monocytes

Publications for Ulcerative Proctitis

Articles related to Ulcerative Proctitis:

(show top 50) (show all 110)
# Title Authors Year
1
Multi Matrix System Mesalazine Plus Rectal Mesalazine in the Treatment of Mild to Moderately Active Ulcerative Proctitis. ( 29339645 )
2018
2
Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository. ( 29393142 )
2018
3
The role of confocal laser endomicroscopy in assessing mucosal healing in patients with ulcerative proctitis. ( 29186737 )
2017
4
Efficacy of topical 5-aminosalicylate monotherapy in patients with ulcerative proctitis with skip inflammation. ( 29205498 )
2017
5
Clinical Predictors and Natural History of Disease Extension in Patients with Ulcerative Proctitis. ( 28922252 )
2017
6
Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. ( 29207381 )
2017
7
Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. ( 28286194 )
2017
8
Therapeutic requirements in active ulcerative proctitis: A single-centre study. ( 28666605 )
2017
9
Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. ( 27489240 )
2016
10
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. ( 27416045 )
2016
11
Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. ( 28089625 )
2016
12
Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. ( 27446860 )
2016
13
Clinical pattern and progression of ulcerative proctitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. ( 26663677 )
2016
14
P214. Ulcerative Proctitis: Predictors and outcomes of disease extension in UC. ( 25717682 )
2015
15
P461. Therapeutic requirements and health resources in the treatment of clinically active ulcerative proctitis. ( 25717954 )
2015
16
Oral 5-aminosalicylate, mesalamine suppository and mesalamine enema as initial therapy for ulcerative proctitis in clinical practice with quality of care implications. ( 26469062 )
2015
17
P587. Tacrolimus suppositories in therapy-resistant ulcerative proctitis - a single center experience. ( 25718087 )
2015
18
Improvement of Refractory Ulcerative Proctitis With Sacral Nerve Stimulation. ( 25930972 )
2015
19
A case of appendectomy as main therapeutic intervention for complex co-morbid ulcerative proctitis. ( 25690705 )
2015
20
Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis. ( 25687266 )
2015
21
Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. ( 25644096 )
2015
22
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. ( 26386854 )
2015
23
Drug Therapies for Ulcerative Proctitis: Systematic Review and Meta-analysis. ( 25072502 )
2014
24
Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. ( 26185880 )
2014
25
Ulcerative proctitis in out-patient practice: an unexpected clinical challenge. ( 25176055 )
2014
26
Ulcerative proctitis: an update on the pharmacotherapy and management. ( 24837209 )
2014
27
Proximal disease extension and related predicting factors in ulcerative proctitis. ( 24325564 )
2014
28
Gastrointestinal symptoms resembling ulcerative proctitis caused by larvae of the drone fly Eristalis tenax. ( 24766340 )
2014
29
Comparison of Xilei-san, a Chinese herbal medicine, and dexamethasone in mild/moderate ulcerative proctitis: a double-blind randomized clinical trial. ( 23383973 )
2013
30
Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued? ( 23576086 )
2012
31
Expanding the therapeutic armamentarium of ulcerative proctitis. ( 23167520 )
2012
32
Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study. ( 22690748 )
2012
33
A rare case of ulcerative proctitis associated with type B lymphomatoid papulosis and superimposed human cytomegalovirus infection. ( 22715829 )
2012
34
Psoriatic colitis mimicking ulcerative proctitis in an elderly patient. ( 22884084 )
2012
35
Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. ( 22775479 )
2012
36
Hydrogen peroxide exposure mimicking ulcerative proctitis. ( 21130717 )
2011
37
Appendicectomy as a potential therapy for refractory ulcerative proctitis. ( 21679209 )
2011
38
A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. ( 20676771 )
2011
39
Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. ( 20848454 )
2010
40
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. ( 20310020 )
2010
41
Recurrent pericarditis in a patient with ulcerative proctitis due to mesalazine suppositories. ( 20237787 )
2010
42
Infliximab for refractory ulcerative proctitis. ( 20222911 )
2010
43
Topically administered infliximab can work in ulcerative proctitis despite the ineffectiveness of intravenous induction therapy. ( 19436284 )
2009
44
Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes. ( 20574506 )
2009
45
Appendicectomy as a therapy for ulcerative proctitis. ( 19584834 )
2009
46
Appendiceal orifice inflammation and ulcerative proctitis. ( 18674731 )
2008
47
Rectal tacrolimus in the treatment of resistant ulcerative proctitis. ( 18761706 )
2008
48
A combination of rectal beclomethasone diproprionate and mesalazine in ulcerative proctitis. ( 18415762 )
2008
49
Ulcerative proctitis: a review of pharmacotherapy and management. ( 18345952 )
2008
50
A suppository Chinese medicine (xilei-san) for refractory ulcerative proctitis: a pilot clinical trial. ( 17675886 )
2007

Variations for Ulcerative Proctitis

Expression for Ulcerative Proctitis

Search GEO for disease gene expression data for Ulcerative Proctitis.

Pathways for Ulcerative Proctitis

GO Terms for Ulcerative Proctitis

Sources for Ulcerative Proctitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....